Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 1-13

  Delea, Thomas E ^a   Hagiwara, May ^a   Dalal, Anand A ^b   Stanford, Richard H ^b   Blanchette, Christopher M ^c  

^a POLICY ANALYSIS INC PAI   (United States)

^b GLAXOSMITHKLINE   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Chronic bronchitis; Cost; Emergency department visit; Health care utilization; Hospitalization; Pharmacoeconomics; Pharmacotherapy

Indexed keywords

ANTIINFECTIVE AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARDIOVASCULAR AGENT; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MONTELUKAST; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG COST; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LINEAR REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; OXYGEN THERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGED; BRONCHITIS; CHRONIC DISEASE; DRUG COMBINATION; HEALTH SERVICE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHITIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 64249113118     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802534020     Document Type: Article

References (31)

1. Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006;129:104-115 (Pubitemid 43265211)
2. Hayes D Jr, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging 2007;24:555-572 (Pubitemid 47195675)
3. National Heart, Lung, and Blood Institute. COPD Fact Sheet. Bethesda, MD: U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 03-5229. March 2003. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd-fact. pdf [Last accessed 8 June 2007]
4. Halpern MT, Higashi MK, Bakst AW, et al. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Manag Care Pharm 2003;9:353-359
5. Halpern MT, Polzin J, Higashi MK, et al. The workplace impact of acute exacerbations of chronic bronchitis (AECB); a literature review. COPD 2004;1:249-254
6. Schmier JK, Halpern MT, Higashi MK, et al. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res 2005;14:329-347 (Pubitemid 40576384)
7. Sin DD, McAlister FA, Man SFP, et al. Contemporary management of chronic obstructive pulmonary disease. Scientific review. JAMA 2003;290:2301-2312
8. Mahler DA, Donohue JF, Goldman MD, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965 (Pubitemid 29193661)
9. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:341-342 (Pubitemid 30129435)
10. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-344 (Pubitemid 30129436)
11. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-191 (Pubitemid 34105586)
12. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/Salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843 (Pubitemid 37123298)
13. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81 (Pubitemid 36150304)
14. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456 (Pubitemid 36173708)
15. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091 (Pubitemid 35178706)
16. Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004;3:173-181 (Pubitemid 39004402)
17. Thirstrup S, Kampmann JP. Combined salmeterol and fluticasone for COPD. Lancet 2003;361:1650-1651
18. MacAllister R. Combined salmeterol and fluticasone for COPD. Lancet 2003;361:1650-1651
19. Complete Prescribing Information and Medication Guide for ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder). Available at: http://www.advair.com/ [Last accessed 8 June 2007]
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
22. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd edn. Cary NC: SAS Institute Inc., 2000
23. McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. London: Chapman and Hall, 1989
24. Lipscomb J, Ancukiewicz M, Parmigiani G, et al. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making 1998;18(Suppl 2):S39-56 (Pubitemid 28175942)
25. Ghali WA, Quan H, Brant R et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-1497 (Pubitemid 33015507)
26. Pasta DJ, Cisternas MG. Estimating Standard Errors for CLASS Variables in Generalized Linear Models Using PROC IML. SAS Users Group International (SUGI 28) Proceedings. March 30 - April 2, 2003. Seattle, Washington. Available at: http://www2.sas.com/proceedings/sugi28/Proceed.pdf [Last accessed December 2004]
27. Efron B, Tibhirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993
28. Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007;4:127-134 (Pubitemid 47164864)
29. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53 (Pubitemid 37046632)
30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497 (Pubitemid 41127293)
31. Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-173